Skip to main content
Premium Trial:

Request an Annual Quote

Genomics England Taps Icon to Manage 100K Genomic Data

NEW YORK (GenomeWeb) – Genomics England said today that it has selected Icon, a provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries, as its data management partner for the 100,000 Genomes Project.

Specifically, Icon will use its data management capabilities and its clinical trials expertise to validate clinical data from 70,000 cancer and rare disease patients and their families who are participating in the UK-led effort.

"We are very proud that our genomics knowledge and our capabilities in securely managing large clinical and real world datasets have been chosen by Genomics England for such an important and transformative project," Brendan Buckley, Icon's chief medical officer, said in a statement. James Peach, Genomics England's managing director for the 100K Genomes Project main program, added that Icon's expertise in data management "will be fundamental in driving scientific research and accelerating the return of results for NHS patients."

Genomics England also has agreements with a number of bioinformatics companies to provide clinical genome interpretation for the project.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.